AltaRex Corp - News Release
AltaRex receives OvaRex clinical data
AltaRex Corp AXO
Shares issued 62,058,898 2000-10-23 close $0.69
Tuesday Oct 24 2000 News Release
Dr. Christopher Nicodemus reports
AltaRex has received new clinical data from its double-blind placebo-controlled lead OvaRex trial for the watchful waiting indication of ovarian cancer. In the active treatment group from the interim analysis population, the company has received summary results from an independent analysis of the data demonstrating a positive association between specific immune responses from OvaRex and clinical benefit. In the active treatment group, more than a doubling in time to relapse is observed in patients demonstrating a specific response characterized by the generation of antibodies to the tumour antigen binding region of OvaRex MAb.
This new result complements the previously reported observation correlating the non-specific human anti-mouse antibody (HAMA) response to patient benefit. At the same time, the company has continued to extend its understanding of the mechanism for its proprietary approach to using foreign antibodies to circulate tumour antigens to elicit tumour-specific immune responses. "The company believes it has now established definitive immunological parameters with which it can evaluate the final results from both of its watchful waiting double-blind placebo-controlled trials expected in the second and third quarter of next year," commented Christopher Nicodemus, MD, senior vice-president, clinical research and development. "These new data also strongly support our decision to conduct a third controlled but open-label trial evaluating the relationship between dosing and these same parameters. The company initiated enrolment in this trial in mid-September and expects to complete enrolment by February of next year."
The company believes that it now has substantial evidence that its proprietary antibody approach is providing specific patient benefit in its continuing OvaRex clinical development program involving five studies and more than 500 patients with advanced ovarian cancer, and that the mechanistic principles established with OvaRex MAb, the company's lead antibody, are also operative with its second product, BrevaRex MAb, the subject of a separate announcement today.
WARNING: The company relies upon litigation protection for "forward-looking" statements.
(c) Copyright 2000 Canjex Publishing Ltd. canada-stockwatch.com
old url (better for printing) |
